{"id":"W2884754452","doi":"10.1177/1352458518789884","title":"Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study","year":2018,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; McGill University; NeuroRx Research (Canada)","funders":"Bayer HealthCare; CSL Behring; IC Design Education Center; Teva Pharmaceutical Industries; Biogen; Sanofi; European Commission; Pfizer","keywords":"Medicine; Placebo; Tolerability; Internal medicine; Adverse effect; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006124824,0.0005903472,0.003075239,0.001196928,0.0007011801,0.00006327979,0.0004072208,0.0002336895,0.0001921689],"category_scores_gemma":[0.01244992,0.0004527992,0.000553932,0.001071375,0.001609776,0.0003565881,0.0006319039,0.0009592842,0.000008783993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001899242,"about_ca_system_score_gemma":0.0002344375,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004333155,"about_ca_topic_score_gemma":0.0003579723,"domain_scores_codex":[0.9925193,0.00119844,0.002865323,0.0008098905,0.001683039,0.0009240135],"domain_scores_gemma":[0.9936368,0.002177608,0.001140593,0.0008376118,0.001625412,0.0005819865],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3624746,0.01292846,0.0611642,0.0001514369,0.001081025,0.00002108089,0.009147295,0.00003598138,0.5005264,0.00000568058,0.0002549161,0.05220892],"study_design_scores_gemma":[0.4907084,0.005009021,0.483032,0.001862493,0.0002858207,0.00002527233,0.001737177,0.004783459,0.0122554,0.00001104251,0.00003208915,0.0002579056],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928914,0.001328427,0.0003091916,0.0004213355,0.0002776819,0.004558532,0.00005115811,0.00005135626,0.0001108867],"genre_scores_gemma":[0.9918573,0.003559456,0.003906989,0.00006590217,0.0003655555,0.0001237378,0.000008416921,0.00008058325,0.00003201596],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4882711,"threshold_uncertainty_score":0.9997924,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1724768760353528,"score_gpt":0.3608088688963201,"score_spread":0.1883319928609673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}